Analysis of treatment effect of urinary kallidinogenase combined with edaravone on massive cerebral infarction

Ke,Jiang; Jing,Mou

doi:10.3892/br.2016.692

Analysis of treatment effect of urinary kallidinogenase combined with edaravone on massive cerebral infarction

Authors:
- Jiang Ke
- Mou Jing
View Affiliations

Affiliations: Department of Neurology, East People's Hospital, Xuzhou, Jiangsu 221000, P.R. China, Department of Cardiology, Xuzhou City Center Hospital, Xuzhou, Jiangsu 221009, P.R. China
Published online on: May 26, 2016 https://doi.org/10.3892/br.2016.692
Pages: 155-158
Copyright: © Ke et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the study was to investigate the clinical effect of urinary kallidinogenase combined with edaravone in the treatment of massive cerebral infarction. A total of 58 patients with massive cerebral infarction were admitted to hospital between January 2013 and January 2014. There were 34 male and 24 female patients. The patients were randomly divided into the observation and control groups (n=29 cases per group). The patients in the control group received edaravone treatment, while patients in the observation group were treated with urinary kallidinogenase and edaravone. The clinical effects of the two groups were then compared. The results showed that the National Institutes of Health Stroke Scale score and serum C‑reactive protein level of the patients in the two groups were significantly decreased following treatment. The decreased degree in the observation group was significantly smaller than that in the control group. The difference was statistically significant [(11.03±3.75) vs. (16.58±7.43) scores, P<0.05; (9.88±4.82) vs. (11.98±4.69) mmol/l, P<0.05]. The serum levels of vascular endothelial growth factor were significantly increased in patients of the two groups after treatment. The increased degree in the observation group was significantly higher than that in the control group. The difference was statistically significant [(268.51±77.34) vs. (188.82±57.33) ng/l, P<0.05]. The total effective rate of the observation group was significantly higher than that of the control group and the difference was statistically significant (89.66 vs. 62.07%, P<0.05). In conclusion, urinary kallidinogenase combined with edaravone treatment has a certain clinical curative effect on massive cerebral infarction.

View Figures

View References

1	Busing KA, Schulte-Sasse C, Fluchter S, Suselbeck T, Haase KK, Neff W, Hirsch JG, Borggrefe M and Duber C: Cerebral infarction: Incidence and risk factors after diagnostic and interventional cardiac catheterization-prospective evaluation at diffusion-weighted MR imaging. Radiology. 235:177–183. 2005. View Article : Google Scholar : PubMed/NCBI
2	Lindley RI, Wardlaw JM, Sandercock PA, Rimdusid P, Lewis SC, Signorini DF and Ricci S: Frequency and risk factors for spontaneous hemorrhagic transformation of cerebral infarction. J Stroke Cerebrovasc Dis. 13:235–246. 2004. View Article : Google Scholar : PubMed/NCBI
3	Hosomi N, Sueda Y, Masugata H, Dobashi H, Murao K, Ueno M, Miki T, Kohno M, Nishiyama A and Matsumoto M: The optimal timing of antihypertensive medication administration for morning hypertension in patients with cerebral infarction. Hypertens Res. 35:720–724. 2012. View Article : Google Scholar : PubMed/NCBI
4	Fukuta T, Asai T, Sato A, Namba M, Yanagida Y, Kikuchi T, Koide H, Shimizu K and Oku N: Neuroprotection against cerebral ischemia/reperfusion injury by intravenous administration of liposomal fasudil. Int J Pharm. 506:129–137. 2016. View Article : Google Scholar : PubMed/NCBI
5	Zhang C, Tao W, Liu M and Wang D: Efficacy and safety of human urinary kallidinogenase injection for acute ischemic stroke: A systematic review. J Evid Based Med. 5:31–39. 2012. View Article : Google Scholar : PubMed/NCBI
6	Subramaniam S and Hill MD: Massive cerebral infarction. Neurologist. 11:150–160. 2005. View Article : Google Scholar : PubMed/NCBI
7	Camerlingo M, Valente L, Tognozzi M, Beretta GL, Moschini L and Cesana BM: C-reactive protein levels in the first three hours after acute cerebral infarction. Int J Neurosci. 121:65–68. 2011. View Article : Google Scholar : PubMed/NCBI
8	Lee BJ, Egi Y, van Leyen K, Lo EH and Arai K: Edaravone, a free radical scavenger, protects components of the neurovascular unit against oxidative stress in vitro. Brain Res. 1307:22–27. 2010. View Article : Google Scholar : PubMed/NCBI
9	Zhang PL, Wang YX, Chen Y, Zhang CH, Li CH, Dong Z, Yin H, Zhang FF and Wang JH: Use of intravenous thrombolytic therapy in acute ischemic stroke patients: Evaluation of clinical outcomes. Cell Biochem Biophys. 72:11–17. 2015. View Article : Google Scholar : PubMed/NCBI
10	Jiao L, Zhang J, Li Z, Liu H, Chen Y and Xu S: Edaravone alleviates delayed neuronal death and long-dated cognitive dysfunction of hippocampus after transient focal ischemia in Wistar rat brains. Neuroscience. 182:177–183. 2011. View Article : Google Scholar : PubMed/NCBI
11	Isahaya K, Yamada K, Yamatoku M, Sakurai K, Takaishi S, Kato B, Hirayama T and Hasegawa Y: Effects of edaravone, a free radical scavenger, on serum levels of inflammatory biomarkers in acute brain infarction. J Stroke Cerebrovasc Dis. 21:102–107. 2012. View Article : Google Scholar : PubMed/NCBI
12	Huang G and Xu W: Edaravone may be an efficacious adjunctive therapeutic agent for decompression sickness: An editorial perspective. Undersea Hyperb Med. 40:215–217. 2013.PubMed/NCBI
13	Ahmad A, Khan MM, Javed H, Raza SS, Ishrat T, Khan MB, Safhi MM and Islam F: Edaravone ameliorates oxidative stress associated cholinergic dysfunction and limits apoptotic response following focal cerebral ischemia in rat. Mol Cell Biochem. 367:215–225. 2012. View Article : Google Scholar : PubMed/NCBI
14	Nakase T, Yoshioka S and Suzuki A: Free radical scavenger, edaravone, reduces the lesion size of lacunar infarction in human brain ischemic stroke. BMC Neurol. 11:392011. View Article : Google Scholar : PubMed/NCBI
15	Kikuchi K, Tancharoen S, Takeshige N, Yoshitomi M, Morioka M, Murai Y and Tanaka E: The efficacy of edaravone (radicut), a free radical scavenger, for cardiovascular disease. Int J Mol Sci. 14:13909–13930. 2013. View Article : Google Scholar : PubMed/NCBI
16	Liu XY, Yao LL, Chen YJ, Tao BB, Yu YC, Bian WH, Yu J and Wang YG: Survivin is involved in the anti-apoptotic effect of edaravone in PC12 cells. Mol Cell Biochem. 327:21–28. 2009. View Article : Google Scholar : PubMed/NCBI
17	Yan Y, Gong K, Ma T, Zhang L, Zhao N, Zhang X, Tang P and Gong Y: Protective effect of edaravone against Alzheimer's disease-relevant insults in neuroblastoma N2a cells. Neurosci Lett. 531:160–165. 2012. View Article : Google Scholar : PubMed/NCBI
18	Kimura K, Aoki J, Sakamoto Y, Kobayashi K, Sakai K, Inoue T, Iguchi Y and Shibazaki K: Administration of edaravone, a free radical scavenger, during t-PA infusion can enhance early recanalization in acute stroke patients - a preliminary study. J Neurol Sci. 313:132–136. 2012. View Article : Google Scholar : PubMed/NCBI
19	Jian Z, Yong R, Chengliang Z, Yu S and Chen WH: Preparation and physicochemical characteristics of the complex of edaravone with hydroxypropyl-β-cyclodextrin. Carbohydr Polym. 83:1101–1105. 2011. View Article : Google Scholar
20	Oster S, Radad K, Scheller D, Hesse M, Balanzew W, Reichmann H and Gille G: Rotigotine protects against glutamate toxicity in primary dopaminergic cell culture. Eur J Pharmacol. 724:31–42. 2014. View Article : Google Scholar : PubMed/NCBI